Evolving Strategies for Leveraging SGLT2 Inhibitor Therapy in Type 2 Diabetes

Get patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk.
Martin J. Abrahamson, MD, FACP

ClinicalThought

SGLT2 inhibitors play important roles in our new person-centric approach for managing T2D. Here’s my take on how SGLT2 inhibitors can be used to mitigate cardiovascular and renal disease, along with how I approach treatment selection in challenging clinical scenarios.

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: November 10, 2020 Expired: November 9, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue